Astria Therapeutics (NASDAQ:ATXS – Get Free Report) was downgraded by equities researchers at Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.
A number of other equities research analysts have also recently issued reports on ATXS. JMP Securities reaffirmed a “market perform” rating on shares of Astria Therapeutics in a report on Wednesday. Jefferies Financial Group cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $30.00 to $13.00 in a report on Tuesday. Oppenheimer cut shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. Citigroup reissued an “outperform” rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, HC Wainwright increased their price target on shares of Astria Therapeutics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Three investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.
Get Our Latest Analysis on Astria Therapeutics
Astria Therapeutics Stock Performance
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. Sell-side analysts predict that Astria Therapeutics will post -1.65 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its position in shares of Astria Therapeutics by 22.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,693 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,222 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Astria Therapeutics by 8.2% during the 2nd quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company’s stock worth $24,238,000 after purchasing an additional 342,000 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Astria Therapeutics by 117.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 103,566 shares of the biotechnology company’s stock worth $555,000 after purchasing an additional 56,006 shares in the last quarter. Bank of America Corp DE grew its position in shares of Astria Therapeutics by 24.9% during the 2nd quarter. Bank of America Corp DE now owns 49,628 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 9,881 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of Astria Therapeutics by 48.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company’s stock worth $4,690,000 after purchasing an additional 286,800 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Featured Stories
- Five stocks we like better than Astria Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- Salesforce’s Long-Awaited Inflection is Here: Rally On!
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Rocket Lab USA Receives Wall Street Validation: Time to Buy?
- What is a support level?
- Archer Buys Rival’s Patent Treasure Trove in Strategic Move
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.